Din Hoxha

Din Hoxha

Auto-generated profile, based on publicly available information

Din Hoxha

Division of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in ACG Case Reports Journal
Verified
Journal Article
Open access
MCMichael Cymbal
Michael Cymbal
ZNZehra Naseem
Zehra Naseem
DHDin Hoxha
Din Hoxha
SGSamita Garg
Samita Garg
This retrospective case series investigates the impact of GLP-1 receptor agonists (GLP-1RAs) on whole-gut gastrointestinal motility using wireless motility capsule testing. We analyzed 10 patients on GLP-1RAs who underwent wireless motility capsule testing for constipation or gastroparesis to assess gastric, small bowel, and colonic transit times. Delayed gastric emptying time was observed in 80% of patients, whereas delayed whole-gut transit time was noted in 44% of patients. The 3 patients on semaglutide (1 mg) had the longest gastric emptying time, delayed whole-gut transit time, and were the only patients with delayed small bowel transit time. Although limited by retrospective observation, our findings are consistent with the effects of GLP-1RAs on gastric motility delay and suggest an impact on whole-gut motility. With the expanding use of GLP-1RAs, these findings underscore the need for prospective studies using emerging motility technologies to further characterize the motility effects both during treatment and after cessation, thereby guiding evidence-based clinical decision-making.

28 August 2025 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
SGSamita Garg
Samita Garg
DHDin Hoxha
Din Hoxha
DLDavid Long
David Long
SVSara Valencia
Sara Valencia
QYQijun Yang
Qijun Yang
DCDian-Jung Chiang
Dian-Jung Chiang
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for managing diabetes and obesity. Although they improve glycemic control, they also delay gastrointestinal motility, potentially leading to inadequate bowel preparation for colonoscopy, which can increase the risk of missed lesions. This study aimed to evaluate the impact of GLP-1RA use on the quality of bowel preparation and on adenomas and sessile serrated polyp (SSP) detection. METHODS: We conducted a retrospective cohort study of outpatient screening and surveillance colonoscopies at a tertiary academic medical center. Adults who used a GLP-1RA within 1 week of their colonoscopy formed the treatment group; patients not on GLP-1RA (nonusers) who never used GLP-1RA served as controls. Propensity score weighting was applied for age, sex, BMI, race, diabetes status, and relevant medications. The subgroup analysis was stratified based on diabetes status and GLP-1RA use. RESULTS: Among 49,987 patients (4,269 GLP-1RA users, 45,718 nonusers), GLP-1RA use was associated with increased odds of inadequate bowel preparation (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.04–1.46). No significant difference in SSP and adenoma detection was observed. In subgroup analysis, GLP-1RA users with diabetes had the highest odds of inadequate preparation (OR 1.88, 95% CI 1.59–2.24) and the lowest odds of SSP detection (OR 0.71, 95% CI 0.57–0.89). DISCUSSION: GLP-1RA use, particularly among patients with diabetes, is associated with higher odds of inadequate bowel preparation and lower SSP detection, whereas adenoma detection was unaffected. Tailored bowel-prep protocols for GLP-1RA users with diabetes should be evaluated prospectively.